Mr. Doyle joined the Trout Group to lead our Boston office in January of 2017. Brennan brings a great depth of experience in the biotech sector after spending the last 12 years as a Healthcare Desk Analyst at Sanford Bernstein. In that role his core focus was on speaking to a wide range of investors about the healthcare research practice and helping clients make investment decisions. Prior to his tenure there Brennan helped to found Stemline Therapeutics (Nasdaq:STML), sold Access Oncology and it’s 4 compounds to Keryx Biopharmaceuticals (NASDAQ: KERX) and helped start a monoclonal antibody company called Accepts. He began his career at Hambrecht & Quest (acquired by JP Morgan) in biotechnology research.
Brennan graduated from Cornell University with a degree in Business and received a Master’s of Science degree from the University of Buffalo’s Roswell Park Cancer Institute. In his spare time, he enjoys skiing, fishing, diving, the Adirondacks, and watching football.